“MC2 Therapeutics has developed world-class innovation in topical therapies with a unique commitment to patient adherence and uncompromised efficacy”, says Trine Ahlgreen. “I’m honored to lead the next phase of the company’s growth, focused on realizing the full global commercial potential of Wynzora Cream for plaque psoriasis, while exploring new opportunities through our proprietary PAD Technology formulation platform with selected partners.”

Trine Ahlgreen

With an extensive background spanning commercial leadership of global, regional and local pharmaceutical product launches, leadership of several successful cross-functional teams and business development across Europe, the US and Japan, Trine brings a breadth of experience to MC2 Therapeutics, states the company.

With solid commercial foundation from large pharma and with a strong track record of strategic leadership and execution, Trine played key roles in several high-impact product launches at Novo Nordisk, including the launches of Ozempic, Rybelsus and the global cardiovascular indication launch for GLP-1. Most recently, at Swiss biotech Micreos Pharmaceuticals AG, Trine built the commercial and business development infrastructure focused on dermatology, forging valuable strategic partnerships across both pharma and OTC.